IP Library › Granted Patent US 9,713,649
Granted Patent B2
US 9,713,649 · App. 14/605,124 · Granted Jul 25, 2017

PSMA-targeting imaging agents

Inventors: Steve Shih-Lin Huang (Cleveland, OH); Warren D. Heston (Cleveland, OH); Xinning Wang (Cleveland, OH)
Assignee: The Cleveland Clinic Foundation
A61K49/0032A61K49/0052A61K51/0406
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,713,649
App. No.
14/605,124
Granted
Jul 25, 2017
Kind
B2
Abstract

A PSMA-specific imaging agent comprising a compound according to formula I: are described, wherein S 1 is an organic spacer group having from 5 to 30 carbons, A is an amino acid forming a portion of a negatively charged peptide oligomer, n is from 3 to 6, S 2 is an organic spacer group having from 5 to 15 carbons, and I is an imaging group, and pharmaceutically acceptable salts thereof. The PSMA-specific imaging agents can be used to image PSMA within a tissue region to guide the treatment of diseases such as prostate cancer.

Claims (2)

1. A PSMA-specific imaging agent comprising a compound having the structure of formula:

and pharmaceutically acceptable salts thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2016
From: HUANG, STEVE SHIH-LIN; HESTON, WARREN D.; WANG, XINNING
To: THE CLEVELAND CLINIC FOUNDATION
Reel/Frame 037489/0237 →
Continuity (2)
Provisional Application 61931112 · Jan 24, 2014
Related Publication 20150209453A1 · Jul 30, 2015